The apoC-III proteoform containing two sialic acid residues (apoC-III2) has different in vitro effects on lipid metabolism compared with asialylated (apoC-III0) or the most abundant monosialylated (apoC-III1) proteoforms. Cross-sectional and longitudinal associations between plasma apoC-III proteoforms (by mass spectrometric immunoassay) and plasma lipids were tested in two randomized clinical trials: ACT NOW, a study of pioglitazone in subjects with impaired glucose tolerance (n = 531), and RACED (n = 296), a study of intensive glycemic control and atherosclerosis in type 2 diabetes patients. At baseline, higher relative apoC-(I)II2 and apoC-III2/apoC-III1 ratios were associated with lower triglycerides and total cholesterol in both cohorts, and with lower small dense LDL in the RACED. Longitudinally, changes in apoC-III2/apoC-III1 were inversely associated with changes in triglycerides in both cohorts, and with total and small dense LDL in the RACED. apoC-III2/apoC-III1 was also higher in patients treated with PPAR-gamma agonists and was associated with reduced cardiovascular events in the RACED control group. Ex vivo studies of apoC-III complexes with higher apoC-III2/apoC-III1 showed attenuated inhibition of VLDL uptake by HepG2 cells and LPL-mediated lipolysis, providing possible functional explanations for the inverse association between a higher apoC-III2/apoC-III1 and hypertriglyceridemia, proatherogenic plasma lipid profiles, and cardiovascular risk.

Of the challenges facing the improvement of human health, none has taken the forefront quite like the endeavor to discover novel treatments for heart disease. As heart disease has now become the leading cause of death throughout the world [1], the medical community has made incredible strides in the mission to treat atherosclerosis which is the major contributor to heart disease. Very Low Density Lipoproteins (VLDL) are secreted by the liver and subsequently converted to Low Density Lipoproteins (LDL). Many factors contribute to the narrowing of the arterial walls, however oxidized LDL is the main factor that leads to the deposition of plaque, leading to atherosclerosis pathologies. Recently, a main focus of research into atherosclerotic processes has been the synthesis and trafficking of VLDL in hepatocytes. The rate-limiting step for the secretion of VLDL from the liver has been determined to be the transport of VLDL from the endoplasmic reticulum (ER) to the Golgi apparatus. VLDL molecules are transported in a specialized transport vesicle the Very Low Density Lipoprotein Transport Vesicle (VTV) [2]. VLDL’s core protein, apolipoproteinB-100 (apoB100), is initially lipidated in the ER, and then subsequently delivered to the Golgi apparatus where the VLDL molecule undergoes maturation involving further lipidation and glycosylation of apoB100. Oxysterol Binding Proteins (OSBP) and the sub family OSBP Related Proteins (ORP) have been implicated in many different trafficking processes, mainly the trafficking of sterols, cholesterol, and lipids. Recently, ORP 10 was shown to be a negative regulator of apoB100 secretion in growth medium [3]. Using co-immunoprecipitation, the current study shows that ORP 10 interacts with VLDL’s core protein apoB100 directly. Employing an in vitro budding assay, we show that the blocking of ORP 10 with a specific antibody against ORP10 increases VTV formation from the ER. Given that the ER to Golgi pathway is the rate-limiting step in overall VLDL secretion, these findings support the conclusion that ORP 10 is a negative regulator of VLDL trafficking between the ER and Golgi, and that this process is mediated by the ORP 10 protein binding with apoB100.

Apolipoprotein B (apoB) is the main protein of very-low-density lipoprotein (VLDL). As apoB is translated and moves through the secretory pathway, lipids from cytoplasmic lipid droplets (LDs) are added to form VLDL particles. Without adequate lipid availability, apoB is misfolded and undergoes proteasomal degradation; however, evidence now shows that apoB can be degraded through autophagy. Inhibiting autophagy decreased apoB localization to autophagosomes in HepG2 cells, but also decreased apoB recovered from cells and media. Inducing autophagy increased apoB localization to autophagosomes and decreased apoB recovery. LDs are also degraded through autophagy however LDs were not affected by autophagy modulation in HepG2 cells. In primary hamster hepatocytes, inhibiting autophagy reduced apoB-autophagosome co-localization and increased LD numbers. These data suggest that autophagy may play a complex role in VLDL assembly by regulating degradation of both apoB and LDs. This dual role is more evident in primary hepatocytes indicating a potential physiological role.

No description available.

No description available.

Apolipoprotein B (apoB) is the main protein of very-low-density lipoprotein (VLDL). As apoB is translated and moves through the secretory pathway, lipids from cytoplasmic lipid droplets (LDs) are added to form VLDL particles. Without adequate lipid availability, apoB is misfolded and undergoes proteasomal degradation; however, evidence now shows that apoB can be degraded through autophagy. Inhibiting autophagy decreased apoB localization to autophagosomes in HepG2 cells, but also decreased apoB recovered from cells and media. Inducing autophagy increased apoB localization to autophagosomes and decreased apoB recovery. LDs are also degraded through autophagy however LDs were not affected by autophagy modulation in HepG2 cells. In primary hamster hepatocytes, inhibiting autophagy reduced apoB-autophagosome co-localization and increased LD numbers. These data suggest that autophagy may play a complex role in VLDL assembly by regulating degradation of both apoB and LDs. This dual role is more evident in primary hepatocytes indicating a potential physiological role.

Les estrogènes confèrent aux femmes une protection cardiovasculaire jusqu’à la ménopause. En effet, la perte des fonctions ovariennes engendre plusieurs désordres du profil lipidique qui s’accompagnent d’une accumulation de triglycérides au foie appelée stéatose hépatique. Le retrait des estrogènes perturbe de nombreuses voies de contrôle de la cholestérolémie, provoquant simultanément une hypercholestérolémie et une stéatose hépatiques. Toutefois, à ce jour, les mécanismes d’action du retrait des estrogènes sur le métabolisme du cholestérol favorisant le stockage de triglycérides au foie demeurent imprécis. À cet égard, les travaux de cette thèse visaient à clarifier l’ensemble des effets du retrait des estrogènes sur le métabolisme du cholestérol pouvant mener à la pathogenèse de la stéatose hépatique. Lors de la première étude, l’ovariectomie (Ovx) chez la rate, un modèle bien établi de la stéatose, avait permis d’identifier la voie d’assemblage des lipoprotéines à très faible densité (VLDL) comme élément contributif à la stéatose. La voie des VLDL reliant étant également une voie de transport du cholestérol, l’étude suivante a été réalisée afin de comprendre le rôle du cholestérol alimentaire sur les lipides hépatiques. Dans cette deuxième étude, le modèle de la diète riche en lipides et en cholestérol (HFHC), aussi reconnu pour induire une stéatose hépatique, a permis d’établir des liens étroits entre le métabolisme du cholestérol et celui des lipides hépatiques. Étonnamment, de manière similaire à l’Ovx, la diète HFHC perturbait la voie d’assemblage des VLDL. En outre, les données recueillies au cours de ces travaux indiquaient qu’une dysrégulation du métabolisme des acides biliaires avait contribué à la sévérité de la stéatose hépatique induite par cette diète HFHC. Dans la continuité de ces deux premiers projets, nous nous sommes intéressés aux effets concomitants du retrait des estrogènes et d’une diète HFHC sur la stéatose hépatique. De manière intéressante, lorsque combinés, l’Ovx et la diète HFHC potentialisaient non seulement l’accumulation de lipides hépatiques, mais également les perturbations moléculaires des voies sous-jacentes à la stéatose, dont l’assemblage des VLDL et de la sécrétion d’acides biliaires. Dans l’ensemble, les données présentées dans la revue de littérature et dans les trois études reliées à cette thèse indiquent qu’une dysrégulation du métabolisme du cholestérol en réponse au retrait des estrogènes entraîne des complications favorisant l’accumulation de lipides dans le foie. / Estrogens confer to women a cardiovascular protection until menopause. Indeed, the loss of ovarian functions leads to several lipid disorders along with hepatic triglycerides accumulation called hepatic steatosis. Estrogen withdrawal disrupts several cholesterol metabolism pathways that results in both hypercholesterolemia and hepatic steatosis. However, to date, the precise mechanisms by which estrogen withdrawal affect cholesterol metabolism pathways that favour lipid storage in the liver are unclear. In this regard, works in the present thesis aimed at elucidate the effects of estrogen withdrawal on cholesterol metabolism involved in hepatic steatosis pathogenesis. In the first study, estrogen withdrawal by ovariectomy (Ovx), a well established model for hepatic steatosis and hypercholesterolemia, had enabled the identification of very low density lipoprotein (VLDL) pathway as a contributory element for hepatic steatosis. Since the VLDL pathway relates lipids and cholesterol metabolism, we conducted the second study to explore the role of dietary cholesterol on hepatic lipids. In the second study, the high fat/high cholesterol (HFHC) diet, also recognized as a model for hepatic steatosis development, was used to explore links between cholesterol metabolism and hepatic fat accumulation. Surprisingly, HFHC diet also disrupted the VLDL pathway. Additionally, data provided in this study indicated that a dysregulation of bile acids metabolism might have contributed to the severity of hepatic steatosis induced by the HFHC diet. As a continuation of these projects, we were interested in the concomitant effects of estrogen withdrawal and HFHC diet on hepatic lipid accretion. Interestingly, when combined, Ovx and HFHC diet not only potentiated hepatic lipid accumulation but also molecular disruptions involved in underlying pathways for hepatic steatosis including the VLDL pathway and bile acid secretion. Overall, data presented in the review of litterature and provided by the three studies related to the present thesis indicate that cholesterol metabolism dysregulation following estrogen withdrawal result in complications that favour hepatic lipid accumulation.

Les estrogènes confèrent aux femmes une protection cardiovasculaire jusqu’à la ménopause. En effet, la perte des fonctions ovariennes engendre plusieurs désordres du profil lipidique qui s’accompagnent d’une accumulation de triglycérides au foie appelée stéatose hépatique. Le retrait des estrogènes perturbe de nombreuses voies de contrôle de la cholestérolémie, provoquant simultanément une hypercholestérolémie et une stéatose hépatiques. Toutefois, à ce jour, les mécanismes d’action du retrait des estrogènes sur le métabolisme du cholestérol favorisant le stockage de triglycérides au foie demeurent imprécis. À cet égard, les travaux de cette thèse visaient à clarifier l’ensemble des effets du retrait des estrogènes sur le métabolisme du cholestérol pouvant mener à la pathogenèse de la stéatose hépatique. Lors de la première étude, l’ovariectomie (Ovx) chez la rate, un modèle bien établi de la stéatose, avait permis d’identifier la voie d’assemblage des lipoprotéines à très faible densité (VLDL) comme élément contributif à la stéatose. La voie des VLDL reliant étant également une voie de transport du cholestérol, l’étude suivante a été réalisée afin de comprendre le rôle du cholestérol alimentaire sur les lipides hépatiques. Dans cette deuxième étude, le modèle de la diète riche en lipides et en cholestérol (HFHC), aussi reconnu pour induire une stéatose hépatique, a permis d’établir des liens étroits entre le métabolisme du cholestérol et celui des lipides hépatiques. Étonnamment, de manière similaire à l’Ovx, la diète HFHC perturbait la voie d’assemblage des VLDL. En outre, les données recueillies au cours de ces travaux indiquaient qu’une dysrégulation du métabolisme des acides biliaires avait contribué à la sévérité de la stéatose hépatique induite par cette diète HFHC. Dans la continuité de ces deux premiers projets, nous nous sommes intéressés aux effets concomitants du retrait des estrogènes et d’une diète HFHC sur la stéatose hépatique. De manière intéressante, lorsque combinés, l’Ovx et la diète HFHC potentialisaient non seulement l’accumulation de lipides hépatiques, mais également les perturbations moléculaires des voies sous-jacentes à la stéatose, dont l’assemblage des VLDL et de la sécrétion d’acides biliaires. Dans l’ensemble, les données présentées dans la revue de littérature et dans les trois études reliées à cette thèse indiquent qu’une dysrégulation du métabolisme du cholestérol en réponse au retrait des estrogènes entraîne des complications favorisant l’accumulation de lipides dans le foie. / Estrogens confer to women a cardiovascular protection until menopause. Indeed, the loss of ovarian functions leads to several lipid disorders along with hepatic triglycerides accumulation called hepatic steatosis. Estrogen withdrawal disrupts several cholesterol metabolism pathways that results in both hypercholesterolemia and hepatic steatosis. However, to date, the precise mechanisms by which estrogen withdrawal affect cholesterol metabolism pathways that favour lipid storage in the liver are unclear. In this regard, works in the present thesis aimed at elucidate the effects of estrogen withdrawal on cholesterol metabolism involved in hepatic steatosis pathogenesis. In the first study, estrogen withdrawal by ovariectomy (Ovx), a well established model for hepatic steatosis and hypercholesterolemia, had enabled the identification of very low density lipoprotein (VLDL) pathway as a contributory element for hepatic steatosis. Since the VLDL pathway relates lipids and cholesterol metabolism, we conducted the second study to explore the role of dietary cholesterol on hepatic lipids. In the second study, the high fat/high cholesterol (HFHC) diet, also recognized as a model for hepatic steatosis development, was used to explore links between cholesterol metabolism and hepatic fat accumulation. Surprisingly, HFHC diet also disrupted the VLDL pathway. Additionally, data provided in this study indicated that a dysregulation of bile acids metabolism might have contributed to the severity of hepatic steatosis induced by the HFHC diet. As a continuation of these projects, we were interested in the concomitant effects of estrogen withdrawal and HFHC diet on hepatic lipid accretion. Interestingly, when combined, Ovx and HFHC diet not only potentiated hepatic lipid accumulation but also molecular disruptions involved in underlying pathways for hepatic steatosis including the VLDL pathway and bile acid secretion. Overall, data presented in the review of litterature and provided by the three studies related to the present thesis indicate that cholesterol metabolism dysregulation following estrogen withdrawal result in complications that favour hepatic lipid accumulation.

Amongst its numerous functions, the liver is responsible for the synthesis and secretion of very low-density lipoprotein (VLDL). VLDL particles play the important role of facilitating the transport of lipids within the aqueous environment of the plasma; yet high plasma concentrations of these particles result in the pathogenesis of atherosclerosis, while low VLDL secretion from the liver results in hepatic steatosis. VLDL synthesis in the hepatocyte is completed in the Golgi apparatus, which serves as the final site of VLDL maturation prior to its secretion to the bloodstream. The mechanism by which VLDL’s targeted transport to the plasma membrane is facilitated has yet to be identified. Our lab has identified this entity. Our findings suggest that upon maturation, VLDL is directed to the plasma membrane through a novel trafficking vesicle, the Post-Golgi VLDL Transport Vesicle (PG-VTV). PG-VTVs containing [3H] radiolabeled VLDL were generated in a cell-free in vitro budding assay for study. First, the fusogenic capabilities of PG-VTVs were established. Vesicles were capable of fusing with the plasma membrane and delivering the VLDL cargo for secretion in a vectorial manner. The next goal of our study is to characterize key regulatory molecular entities necessary for PG-VTV biosynthesis. A detailed analysis was undertaken to determine the PG-VTV proteome via western blot and two-dimensional difference in gel electrophoresis. The identification of key molecular regulators will potentially offer therapeutic targets to control VLDL secretion to the bloodstream.